Sign In
Buy MIRM
$91.84
-0.335 (-0.363%)
At Close: Jun 03, 2026
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
07:44pm, Thursday, 04'th May 2023
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to loss of $1.17 per share a year ago.
Mirum's (MIRM) Livmarli Gets FDA Nod for Expanded Use, Stock Up
10:42am, Wednesday, 15'th Mar 2023
Mirum Pharmaceuticals (MIRM) announces FDA approval of Livmarli for infants 3 months and older. Stock up 6% in response to the news.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Call Transcript
10:40pm, Wednesday, 08'th Mar 2023
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Corporate Participants Andrew McKibben - Vice President, Investor Relations and Finance Chris Peetz - Presi
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates
09:49pm, Wednesday, 08'th Mar 2023
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of -1.02% and 11.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th
Why Mirum Pharmaceuticals (MIRM) Might Surprise This Earnings Season
11:18am, Thursday, 02'nd Mar 2023
Mirum Pharmaceuticals (MIRM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma
07:00am, Wednesday, 01'st Feb 2023
Albireo, Mirum Pharmaceuticals, Inc.'s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. The biggest value driver of Mirum is Livmarli, currently the only
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023
04:02pm, Tuesday, 03'rd Jan 2023
FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel t
Mirum: Potential For European Approval To Move It Forward
04:49am, Sunday, 20'th Nov 2022
Mirum raised 2022 full year net product sales guidance estimate for LIVMARLI to $70 million. Potential to receive European approval of LIMVARLI for Alagille syndrome in patients aged 2 months and olde
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
08:50am, Friday, 18'th Nov 2022
FOSTER CITY, Calif.--( BUSINESS WIRE )--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel t
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2022 Earnings Call Transcript
04:12pm, Wednesday, 09'th Nov 2022
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Ian Clements - CFO Chris Peetz - President, CEO & Director Peter Radovich -
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:01pm, Tuesday, 30'th Aug 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel the
CyberOptics, Mirum Pharmaceuticals See Activist Action
06:20pm, Friday, 26'th Aug 2022
These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities.
Mirum: Great Sales Start For Livmarli Paves The Way For Long-Term Growth
02:03pm, Wednesday, 17'th Aug 2022
Following the public offering, Mirum is in an excellent financial position to accelerate both the Livmarli launch and the clinical development pipeline. The biggest value driver is Livmarli, currently
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2022 Results - Earnings Call Transcript
08:00am, Sunday, 07'th Aug 2022
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Ian Clements - CFO Chris Peetz - President and CEO Peter Radovich - COO Pam V
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
07:33pm, Thursday, 04'th Aug 2022
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 20% and 11.58%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock
